+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Identification of candidate genes using the murine model of female genital tract infection with Chlamydia trachomatis



Identification of candidate genes using the murine model of female genital tract infection with Chlamydia trachomatis



Drugs of Today 45 Suppl B: 51-59



The integrated approach to the study of female genital tract infection (GTI) with Chlamydia trachomatis is a conceptual framework through which a consistent and comprehensive evidence-based understanding of C. trachomatis GTI could evolve. One application of this approach has been to identify candidate genes that may play a role in the course and severity of C. trachomatis GTI in women, using human clinical and genetic data together with results obtained in the female mouse model to guide the selection process This model has been proven robust enough: i) to identify stable phenotypic differences in the course and outcome of GTI among commonly used immunocompetent inbred mouse stains that are used in the construction of gene knockout (KO) and transgenic mice; as well as ii) to serve as a platform in which to assess the influence of genetic differences among human genital tract isolates of C. trachomatis as well as between this biovar and the mouse biovar, Chlamydia muridarum. This review presents a summary of published and unpublished results from 25 years of studies in immunodeficient and gene-deficient KO mice that both inform our present understanding of the immunogenetics of C. trachomatis GTI and serve to guide candidate gene selection.

(PDF emailed within 1 workday: $29.90)

Accession: 053663931

Download citation: RISBibTeXText

PMID: 20011695


Related references

Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: Serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection. Vaccine 13(11): 1023-1032, 1995

Imiquimod does not affect shedding of viable chlamydiae in a murine model of Chlamydia trachomatis genital tract infection. Infectious Diseases in Obstetrics and Gynecology 11(2): 81-87, 2003

Female genital tract infection with chlamydia trachomatis. Journal of Saitama Medical School 17(1): 71-78, 1990

Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection. Infection and Immunity 63(12): 4704-4714, 1995

Immunization with the attenuated plasmidless Chlamydia trachomatis L2 strain provides partial protection in a murine model of female genitourinary tract infection. Vaccine: 6, 1454-1462, 2010

Chlamydia trachomatis antigen in female genital tract infection. Indian Journal of Dermatology, Venereology and Leprology 62(2): 95-97, 1996

Immunization with the attenuated plasmidless Chlamydia trachomatis L2(25667R) strain provides partial protection in a murine model of female genitourinary tract infection. Vaccine 28(6): 1454-1462, 2010

Survey of the treatment of Chlamydia trachomatis infection of the female genital tract. Acta Obstetricia et Gynecologica Scandinavica 71(5): 356-360, 1992

Comparison of chlamydia trachomatis ct genital tract infection gti in different strains of female mice. Abstracts of the General Meeting of the American Society for Microbiology 91: 68, 1991

An integrated approach to the study of Chlamydia trachomatis infection of the female genital tract. Drugs of Today 42 Suppl A: 83-97, 2006

Animal models for studying female genital tract infection with Chlamydia trachomatis. Infection and Immunity 81(9): 3060-3067, 2014

Chlamydia trachomatis infection of the female genital tract. Pathogenetic and clinicopathologic correlations. Pathology Annual 22 Pt 1: 193-223, 1987

Prior genital tract infection with a murine or human biovar of Chlamydia trachomatis protects mice against heterotypic challenge infection. Infection and Immunity 67(6): 3019-3025, 1999

Efficacy of an immune modulator in experimental Chlamydia trachomatis infection of the female genital tract. Infectious Diseases in Obstetrics and Gynecology 2006(): 61265-61265, 2006

Hypothesis: Chlamydia trachomatis infection of the female genital tract is controlled by Type 2 immunity. Medical Hypotheses 79(6): 713-716, 2013